NCT06233929

Rheumatoid Arthritis Real-world Cohort Study in China (ReALSA)

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University·ClinicalTrials.govNot yet recruiting
View on ClinicalTrials.gov
Study focus
Disease/Condition
Rheumatoid Arthritis
Study type
Observational
Sponsor & location
Primary sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Timeline & enrollment
Phase
N/A
Start date
Mar 01, 2024
End date
Mar 01, 2033
Enrollment
2000 participants
Primary outcome

Myopenia,CVDs

Summary

An ongoing long-term cohort study is conducted in the Sun Yat-sen Memorial Hospital of Sun
 Yat-sen University, that is dedicated to recruiting RA patients, to identify the development
 of clinical, neuroimaging, and biochemical biomarkers for the diagnosis and prognosis of RA,
 especially for those with sarcopenia/myopenia
 
 To improve the prognosis of RA, this study includes the following objectives:
 
 1. Construct a useful database to explore the secular dynamic progress of RA, especially
 the difference between early and lately RA, as well as to improve our understanding of
 the life-course factors affecting the process that will facilitate future research
 activities.
 
 2. Identify the potential markers (clinical, biomedical and imaging) affecting/predicting
 the development process of sarcopenia/myopenia or other prognosis in RA patients.
 
 3. Develop the related multi-modal prediction models with clinical, biomedical and imaging
 variables to improve the diagnosis and prognosis of RA.

ICD-10 classifications
Rheumatoid arthritis, unspecifiedOther rheumatoid arthritisOther specified rheumatoid arthritisRheumatoid arthritis with involvement of other organs and systemsSeronegative rheumatoid arthritis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06233929
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06233929 through Pure Global AI's free database. This phase not specified trial is sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University and is currently Not yet recruiting. The study focuses on Rheumatoid Arthritis. Target enrollment is 2000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.